The new European guidelines for prevention of cardiovascular disease are misleading.

Magle Stora Kyrkogata 9 , Lund, Sweden. Prince Sultan Cardiac Center , Hofuf, Alhasar, Saudi Arabia. Laboratoire Coeur et Nutrition, TIMC-CNRS, Université Grenoble-Alpes, Faculté de Médecine , La Tronche, France. Departments of Psychology, Molecular Pharmacology & Physiology, PCD 4118G, University of South Florida , Tampa, FL, USA. Japan Institute of Pharmacovigilance, Osaka, Japan. Department of Internal Medicine, Toyama Jonan Onsen Daini Hospital, University of Toyama , Toyama City, Japan. Strömstad Academy, Östervåla, Sweden. Church Farm, Llanvaches , Gwent,UK. 24 Prestwick Close, Tytherington, Macclesfield, UK. 1107, Doctors Dr, Tyler, Texas, USA. Veterans Affairs Boston Healthcare System, Harvard Medical School , Boston, MA, USA. Faculty of Pharmaceutical Science, Nagoya City University, 1-89 Kaminokura , Midoriku, Nagoya, Japan. Department of Vascular & Endovascular Surgery, National University of Ireland , Galway, Ireland. Verandastigen 3, Rönninge, Sweden.

Expert review of clinical pharmacology. 2020;(12):1289-1294
Full text from:

Abstract

Introduction: The European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) have recently published three major revisions of their guidelines for the management of chronic heart disease, blood lipids, and diabetes. Areas covered: We have scrutinized these guidelines in detail and found that the authors have ignored many studies that are in conflict with their conclusions and recommendations. Expert commentary: The authors of the guidelines have ignored that LDL-cholesterol (LDL-C) of patients with acute myocardial infarction is lower than normal; that high cholesterol is not a risk factor for diabetics; that the degree of coronary artery calcification is not associated with LDL-C; and that 27 follow-up studies have shown that people with high total cholesterol or LDL-C live just as long or longer than people with low cholesterol. They have also ignored the lack of exposure-response in the statin trials; that several of these trials have been unable to lower CVD or total mortality; that no statin trial has succeeded with lowering mortality in women, elderly people, or diabetics; and that cholesterol-lowering with statins has been associated with many serious side effects.

Methodological quality

Publication Type : Review

Metadata